Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
05 03 2019
05 03 2019
Historique:
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
15
3
2019
Statut:
ppublish
Résumé
Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017). Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21 individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256), supplements without therapy (n = 256), and supplements with therapy (n = 256). Cumulative 1-year onset of MDD via the Mini International Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded variables (-1 indicating control, 1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779 (76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%) patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI, 0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14; P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four patients in each of the placebo groups and 24 patients in the supplementation with therapy group were hospitalized, and 26 patients in the supplementation-only group were hospitalized. Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. ClinicalTrials.gov Identifier: NCT02529423.
Identifiants
pubmed: 30835307
pii: 2726983
doi: 10.1001/jama.2019.0556
pmc: PMC6439597
doi:
Banques de données
ClinicalTrials.gov
['NCT02529423']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
858-868Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
Contemp Clin Trials Commun. 2018 Mar 28;10:80-85
pubmed: 29696162
Am J Psychiatry. 2008 Oct;165(10):1272-80
pubmed: 18765483
J Clin Psychiatry. 2008 Aug;69(8):1203-9
pubmed: 18557664
Eur J Clin Nutr. 2011 Jun;65(6):750-6
pubmed: 21427744
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Transl Psychiatry. 2016 Mar 15;6:e756
pubmed: 26978738
BMC Med. 2017 Jan 30;15(1):23
pubmed: 28137247
Br J Psychiatry. 2015 Apr;206(4):324-31
pubmed: 25573400
Annu Rev Public Health. 2008;29:115-29
pubmed: 18348707
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Res Publ Assoc Res Nerv Ment Dis. 1983;60:115-20
pubmed: 6823524
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Prev Med. 2015 Jul;76 Suppl:S22-32
pubmed: 25445331
Public Health Nutr. 2015 Aug;18(11):2074-93
pubmed: 25465596
Am J Psychiatry. 2016 Jun 1;173(6):575-87
pubmed: 27113121
Stat Methods Med Res. 2010 Jun;19(3):237-70
pubmed: 19608601
JAMA. 2012 Mar 14;307(10):1033-4
pubmed: 22416097
J Nutr. 2004 Sep;134(9):2372-80
pubmed: 15333731
J Affect Disord. 2016 Jul 1;198:1-14
pubmed: 26998791
Mol Psychiatry. 2014 Apr;19(4):444-51
pubmed: 23568194
Mol Psychiatry. 2019 Jan;24(1):18-33
pubmed: 29453413
Int J Epidemiol. 2014 Apr;43(2):318-29
pubmed: 24760873
Nutr Neurosci. 2019 Jul;22(7):474-487
pubmed: 29215971
Br J Nutr. 2008 Feb;99(2):421-31
pubmed: 17956647
Biol Psychiatry. 2006 Jan 15;59(2):147-54
pubmed: 16181615
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
Am J Prev Med. 2014 Oct;47(4):498-504
pubmed: 25092122
PLoS One. 2014 Jun 17;9(6):e100100
pubmed: 24936656
Arch Gen Psychiatry. 2009 Mar;66(3):297-304
pubmed: 19255379
JAMA. 2016 May 3;315(17):1854-63
pubmed: 27139058
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
BMC Psychiatry. 2016 Jun 08;16:192
pubmed: 27277946
J Psychiatr Res. 2018 Feb;97:38-46
pubmed: 29175296
J Affect Disord. 2018 Jan 15;226:346-354
pubmed: 29031185